We have seen that with semaglutide
CAA progression is promoted as A deposition in vessel walls impairs endothelial mitochondrial function, reducing NO production and causing vasoconstriction
GIP adds another layer, also boosting insulin secretion but with a more nuanced effect on energy balance and fat storage
URLs: Tickets: Brochure: Prices: Drug Developer Pricing* - Conference + 2 Workshops : USD 4197.00, Drug Developer Pricing* - Conference + 1 Workshop: USD 3598.00, Drug Developer Pricing* - Conference Only: USD 2999.00, Academic Pricing** - Conference + 2 Workshops: USD 3597.00, Academic Pricing** - Conference + 1 Workshop Only: USD 3098.00, Academic Pricing** - Conference Only: USD 2599.00, Solution Provider Pricing - Conference + 2 Workshops: USD 5097.00, Solution Provider Pricing - Conference + 1 Workshop: USD 4398.00, Solution Provider Pricing - Conference Only: USD 3699.00 Speakers: Adam Bell, Vice President, Translational Medicine and Regulatory Affairs, Neuraly, Andrew Young, Chief Scientific and Medical Officer, I2O Therapeutics, Belle van Rosmalen, Director - Incretin Outcomes, Eli Lilly and Co., Damian Bialonczyk, Global Medical Lead - Metabolism, Roche, David Glass, Vice President - Research, Regeneron, Elisa Araldi, Professor, University of Parma, Hong Chen, Director - Search and Evaluation, Novo Nordisk, Jason Mastaitis, Sr
